Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Inovio Pharmaceuticals, Inc. (INO)
USD1.16
+0.00 (+0.43%)
US NASDAQ Healthcare Biotechnology
Address
660 West Germantown Pike 19462
Plymouth Meeting, PA, US
Plymouth Meeting, PA, US
CEO
Jacqueline E. Shea
Website
inovio.com
IPO
1998-12-08
CIK 1055726 ISIN US45773H4092
Also trades on
Frankfurt Stock Exchange · GBM.F (EUR)
Frankfurt Stock Exchange · GBMB.F (EUR)
NASDAQ Global Select · INO (USD)
Description
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Date | Filing |
|---|---|---|
| VGX | 2008-12-10 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.16
+0.00 (+0.43%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
1.47
Float Shares
53.31M
Free Float %
99.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.96% | -4.96% | +22.94% | -16.77% | -31.28% | -22.99% | -30.21% | -85.50% | -98.21% | -98.80% | -99.81% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (17 ratings, all time)
Buy
Price Targets & DCF
Current price
1.16
Low
6.00
+417.2%
Consensus
6.00
+417.2%
Median
6.00
+417.2%
High
6.00
+417.2%
DCF (Unlevered)
0.07
-94.0%
DCF (Levered)
0.07
-93.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
6.00
+417.2%
|
| All Time | 5 |
15.60
+1,244.8%
|
Quality scores
Altman Z-Score
-53.03
Distress
Piotroski F-Score
0 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-70.0% Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+54.2% ★ Q1'26: +100.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-139,971.5%
-
EBIT margin Biotechnology: +0.0%-130,000.0%
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1,626.3% Q1'26: +2,444.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.11× Q1'26: -0.10× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
40.57M
est: 41.61M (-2.5%)
|
35.37M
est: 32.81M (+7.8%)
|
42.22M
est: 40.41M (+4.5%)
|
30.48M
est: 30.88M (-1.3%)
|
4.11M
est: 6.00M (-31.4%)
|
7.41M
est: 3.21M (+130.8%)
|
1.77M
est: 3.33M (-46.8%)
|
10.26M
est: 10.55M (-2.8%)
|
832.0K
est: 717.1K (+16.0%)
|
217.8K
est: 133.5K (+63.2%)
|
65.3K
est: 86.0K (-24.0%)
|
10.88M
733.5K – 30.45M
+12,556.5% YoY
|
68.22M
44.14M – 92.31M
+526.8% YoY
|
150.72M
150.72M – 150.72M
+120.9% YoY
|
204.05M
109.15M – 336.65M
+35.4% YoY
|
229.36M
122.69M – 378.42M
+12.4% YoY
|
| EBITDA |
-33.37M
est: -41.61M (+19.8%)
|
-74.15M
est: -32.81M (-126.0%)
|
-84.74M
est: -40.41M (-109.7%)
|
-89.80M
est: -30.88M (-190.8%)
|
-107.34M
est: -6.00M (-1,689.7%)
|
-149.56M
est: -3.21M (-4,556.9%)
|
-296.56M
est: -3.33M (-8,793.5%)
|
-270.90M
est: -10.55M (-2,467.2%)
|
-130.39M
est: -717.1K (-18,083.9%)
|
-103.95M
est: -133.5K (-77,781.6%)
|
-81.96M
est: -86.0K (-95,198.9%)
|
-10.88M
-30.45M – -733.5K
-12,556.5% YoY
|
-68.22M
-92.31M – -44.14M
-526.8% YoY
|
-150.72M
-150.72M – -150.72M
-120.9% YoY
|
-204.05M
-336.65M – -109.15M
-35.4% YoY
|
-229.36M
-378.42M – -122.69M
-12.4% YoY
|
| EBIT |
-35.28M
est: -41.61M (+15.2%)
|
-77.24M
est: -32.81M (-135.4%)
|
-88.18M
est: -40.41M (-118.2%)
|
-94.80M
est: -30.88M (-206.9%)
|
-112.86M
est: -6.00M (-1,781.6%)
|
-154.19M
est: -3.21M (-4,701.0%)
|
-301.29M
est: -3.33M (-8,935.3%)
|
-276.40M
est: -10.55M (-2,519.3%)
|
-133.89M
est: -717.1K (-18,572.5%)
|
-107.08M
est: -133.5K (-80,126.8%)
|
-84.95M
est: -86.0K (-98,674.3%)
|
-10.88M
-30.45M – -733.5K
-12,556.5% YoY
|
-68.22M
-92.31M – -44.14M
-526.8% YoY
|
-150.72M
-150.72M – -150.72M
-120.9% YoY
|
-204.05M
-336.65M – -109.15M
-35.4% YoY
|
-229.36M
-378.42M – -122.69M
-12.4% YoY
|
| Net Income |
-29.19M
est: -128.74M (+77.3%)
|
-73.74M
est: -314.52M (+76.6%)
|
-88.21M
est: -369.18M (+76.1%)
|
-96.97M
est: -315.51M (+69.3%)
|
-119.36M
est: -345.02M (+65.4%)
|
-166.41M
est: -375.23M (+55.7%)
|
-303.66M
est: -407.41M (+25.5%)
|
-279.82M
est: -361.13M (+22.5%)
|
-135.12M
est: -2.90B (+95.3%)
|
-107.25M
est: -1.99B (+94.6%)
|
-84.95M
est: -1.07B (+92.1%)
|
-539.85M
-643.77M – -435.94M
+49.5% YoY
|
-45.13M
-445.78M – -4.33M
+91.6% YoY
|
28.62M
28.13M – 361.03M
+163.4% YoY
|
322.58M
127.55M – 595.12M
+1,027.3% YoY
|
408.86M
161.67M – 754.30M
+26.7% YoY
|
| SGA |
18.06M
est: 2.26B (-99.2%)
|
23.89M
est: 1.78B (-98.7%)
|
28.29M
est: 2.19B (-98.7%)
|
29.32M
est: 1.68B (-98.2%)
|
27.20M
est: 325.32M (-91.6%)
|
37.25M
est: 174.19M (-78.6%)
|
53.75M
est: 180.86M (-70.3%)
|
90.19M
est: 572.34M (-84.2%)
|
47.58M
est: 71.76B (-99.9%)
|
37.00M
est: 20.46M (+80.9%)
|
32.68M
est: 13.18M (+147.9%)
|
1.67B
112.41M – 4.67B
+12,556.5% YoY
|
10.46B
6.76B – 14.15B
+526.8% YoY
|
23.10B
23.10B – 23.10B
+120.9% YoY
|
31.27B
16.73B – 51.60B
+35.4% YoY
|
35.15B
18.80B – 58.00B
+12.4% YoY
|
| EPS |
-0.43
est: -4.74 (+90.9%)
|
-1.01
est: -11.58 (+91.3%)
|
-1.08
est: -13.59 (+92.1%)
|
-1.05
est: -11.62 (+91.0%)
|
-0.97
est: -12.70 (+92.4%)
|
-1.07
est: -13.82 (+92.3%)
|
-1.42
est: -15.00 (+90.5%)
|
-14.07
est: -13.30 (-5.8%)
|
-6.09
est: -5.53 (-10.2%)
|
-3.95
est: -4.21 (+6.1%)
|
-1.81
est: -2.27 (+20.3%)
|
-1.15
-1.37 – -0.93
+49.5% YoY
|
-0.48
-0.95 – -0.01
+58.1% YoY
|
0.33
0.06 – 0.77
+169.4% YoY
|
0.69
0.27 – 1.27
+106.4% YoY
|
0.87
0.34 – 1.61
+26.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-21.66B
OE per share TTM
-32.27
Owner's Yield
-2,338.69%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
539.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
55
Total invested
7.55M
Insider transactions (90d)
0
Beneficial owners (>5%)
23
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | STATE STREET CORPORATION | 23.27M | 10.49% | — | 22.83M | — | 23.27M | HC | BOSTON, MASSACHUSETTS | 2022-04-11 | ↗ |
| 2 | SSGA FUNDS MANAGEMENT, INC. | 19.42M | 8.76% | — | 19.38M | — | 19.42M | IA | BOSTON, MASSACHUSETTS | 2022-04-11 | ↗ |
| 3 | Dr. J. Joseph Kim | 15.08M | 16.90% | 11.63M | — | 15.08M | 10.00 | IN | United States | 2009-06-10 | ↗ |
| 4 | the Stockholders listed therein. | 8.00M | 9.30% | 8.00M | — | — | 10.00 | OO | Delaware | 2009-06-10 | ↗ |
| 5 | The Vanguard Group | 4.32M | 5.77% | 2.00 | 7.00 | — | 21.13M | IA | 00 | 2011-02-10 | ↗ |
| 6 | Wasatch Advisors, Inc. 87-0319391 | 3.94M | 2.30% | 3.94M | — | 3.94M | — | IA | — | 2021-02-11 | ↗ |
| 7 | David Kroin | 2.59M | 9.99% | — | 2.59M | — | — | HC, IN | United States | 2024-04-26 | ↗ |
| 8 | Deep Track Biotechnology Master Fund, Ltd. | 2.59M | 9.99% | — | 2.59M | — | — | CO | Cayman Islands | 2024-04-26 | ↗ |
| 9 | Deep Track Capital, LP | 2.59M | 9.99% | — | 2.59M | — | — | IA, OO | Delaware | 2024-04-26 | ↗ |
| 10 | Andrew Zacks | 2.32M | 5.86% | — | 2.32M | — | 2.32M | IN | United States of America | 2007-03-26 | ↗ |
| 11 | Conus Partners, Inc. | 2.32M | 5.86% | — | 2.32M | — | 2.32M | CO | New York | 2007-03-26 | ↗ |
| 12 | Zesiger Capital Group LLC | 2.25M | 6.20% | — | — | — | — | IA | New York, New York | 2007-02-13 | ↗ |
| 13 | 22-1024240 | 2.24M | 4.50% | — | 2.24M | — | 2.24M | CO | New Jersey | 2003-02-04 | ↗ |
| 14 | (1) BlackRock, Inc. | 1.89M | 7.30% | 1.86M | — | 1.89M | — | HC | Delaware | 2024-11-08 | ↗ |
| 15 | Mr. Steven Derby | 1.79M | 4.89% | — | 1.79M | — | 1.79M | IN | United States | 2006-11-22 | ↗ |
| 16 | SDS Capital Group SPC, Ltd. | 1.79M | 4.89% | 1.79M | — | 1.79M | — | CO | Cayman Islands | 2006-11-22 | ↗ |
| 17 | SDS Management, LLC | 1.79M | 4.89% | — | 1.79M | — | 1.79M | CO | Delaware | 2006-11-22 | ↗ |
| 18 | Merck & Co., Inc. | 1.69M | 5.64% | — | — | — | — | CO | : | 2006-01-09 | ↗ |
| 19 | Capital Ventures International | — | 0.00% | — | — | — | — | CO | Cayman Islands | 2016-02-12 | ↗ |
| 20 | Heights Capital Management, Inc. | — | 0.00% | — | — | — | — | CO | Delaware | 2016-02-12 | ↗ |
| 21 | Nikko Asset Management Americas, Inc. | — | 0.00% | — | — | — | — | IA | USA | 2021-02-11 | ↗ |
| 22 | Nikko Asset Management Co., Ltd. (“NAM”) | — | 0.00% | — | — | — | — | FI, IA, HC | Japan | 2021-02-05 | ↗ |
| 23 | Sumitomo Mitsui Trust Holdings, Inc. (“SMTH”) | — | 0.00% | — | — | — | — | FI, HC | Japan | 2021-02-05 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
55
-51 vs prev Q
New positions
8
Closed positions
56
Increased
16
Reduced
9
Put/Call ratio
3.52
Calls held
11.6K
Puts held
40.8K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FMR LLC | 9.85M +9.8M (+756,753.5%) | 17.13M +17.1M (+562,751.3%) | 18.87% +18.871 pp | 0.00% +0.001 pp | USD1.74 +0.0% | 8 qtrs — |
| 2 | JANUS HENDERSON GROUP PLC | 3.31M +42.1K (+1.3%) | 5.77M -1.9M (-24.3%) | 6.34% -2.070 pp | 0.00% -0.001 pp | USD2.33 -25.3% | 2 qtrs — |
| 3 | VANGUARD GROUP INC | 3.32M +602.7K (+22.2%) | 5.77M -579.0K (-9.1%) | 6.36% -0.631 pp | 0.00% +0.000 pp | USD7.10 -75.5% | 8 qtrs — |
| 4 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.55M -875.0K (-25.5%) | 4.44M -3.6M (-44.6%) | 4.89% -3.935 pp | 0.01% -0.006 pp | USD2.34 -25.6% | 2 qtrs — |
| 5 | BOXER CAPITAL MANAGEMENT, LLC | 2.42M +120.1K (+5.2%) | 4.21M -1.2M (-21.8%) | 4.64% -1.284 pp | 0.92% -0.794 pp | USD2.31 -24.7% | 2 qtrs — |
| 6 | D. E. SHAW & CO., INC. | 2.23M +1.4M (+176.6%) | 3.88M +2.0M (+105.7%) | 4.28% +2.200 pp | 0.00% +0.001 pp | USD1.96 -11.2% | 2 qtrs — |
| 7 | MILLENNIUM MANAGEMENT LLC | 1.40M -569.1K (-28.9%) | 2.44M -2.2M (-47.1%) | 2.69% -2.390 pp | 0.00% -0.001 pp | USD2.29 -24.0% | 3 qtrs — |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 769.4K +222.6K (+40.7%) | 1.34M +60.1K (+4.7%) | 1.47% +0.067 pp | 0.00% +0.000 pp | USD5.37 -67.6% | 8 qtrs — |
| 9 | BLACKROCK, INC. | 617.9K +118.5K (+23.7%) | 1.08M -93.5K (-8.0%) | 1.18% -0.102 pp | 0.00% +0.000 pp | USD4.38 -60.3% | 6 qtrs — |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 553.2K -263.2K (-32.2%) | 962.5K -947.7K (-49.6%) | 1.06% -1.042 pp | 0.00% -0.001 pp | USD2.84 -38.7% | 8 qtrs — |
| 11 | GSA CAPITAL PARTNERS LLP | 459.8K +16.7K (+3.8%) | 800.0K -237.0K (-22.9%) | 0.88% -0.260 pp | 0.07% -0.018 pp | USD2.21 -21.3% | 3 qtrs — |
| 12 | TWO SIGMA INVESTMENTS, LP | 322.7K +31.9K (+11.0%) | 561.6K -118.9K (-17.5%) | 0.62% -0.130 pp | 0.00% 0.000 pp | USD2.12 -17.9% | 8 qtrs — |
| 13 | NORTHERN TRUST CORP | 300.0K +61.5K (+25.8%) | 522.0K -36.0K (-6.5%) | 0.58% -0.039 pp | 0.00% +0.000 pp | USD3.79 -54.1% | 8 qtrs — |
| 14 | 683 CAPITAL MANAGEMENT, LLC | 248.8K +248.8K (+100.0%) | 432.9K +432.9K (+100.0%) | 0.48% +0.477 pp | 0.02% +0.019 pp | USD1.74 +0.0% | 1 qtrs NEW |
| 15 | STATE STREET CORP | 247.4K +61.2K (+32.9%) | 430.5K -5.2K (-1.2%) | 0.47% -0.005 pp | 0.00% +0.000 pp | USD5.41 -67.8% | 8 qtrs — |
| 16 | OMERS ADMINISTRATION CORP | 223.0K +223.0K (+100.0%) | 388.0K +388.0K (+100.0%) | 0.43% +0.428 pp | 0.00% +0.003 pp | USD1.74 +0.0% | 1 qtrs NEW |
| 17 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 173.0K +173.0K (+100.0%) | 301.0K +301.0K (+100.0%) | 0.33% +0.332 pp | 0.01% +0.006 pp | USD1.74 +0.0% | 1 qtrs NEW |
| 18 | UBS GROUP AG | 170.6K -122.5K (-41.8%) | 296.8K -389.0K (-56.7%) | 0.33% -0.428 pp | 0.00% 0.000 pp | USD2.29 -24.0% | 8 qtrs — |
| 19 | XTX TOPCO LTD | 167.0K -43.5K (-20.7%) | 290.6K -202.1K (-41.0%) | 0.32% -0.222 pp | 0.01% -0.018 pp | USD2.28 -23.7% | 5 qtrs — |
| 20 | PERSISTENT ASSET PARTNERS LTD | 142.2K +142.2K (+100.0%) | 247.4K +247.4K (+100.0%) | 0.27% +0.273 pp | 0.11% +0.111 pp | USD1.74 +0.0% | 1 qtrs NEW |
| 21 | JACOBS LEVY EQUITY MANAGEMENT, INC | 130.8K +113.1K (+640.1%) | 227.6K +186.2K (+450.3%) | 0.25% +0.205 pp | 0.00% +0.001 pp | USD1.82 -4.4% | 2 qtrs — |
| 22 | QUBE RESEARCH & TECHNOLOGIES LTD | 115.5K +82.0K (+244.7%) | 200.9K +122.5K (+156.3%) | 0.22% +0.135 pp | 0.00% +0.000 pp | USD1.83 -4.9% | 8 qtrs — |
| 23 | MORGAN STANLEY | 105.8K -680.9K (-86.5%) | 184.1K -1.7M (-90.0%) | 0.20% -1.823 pp | 0.00% 0.000 pp | USD3.25 -46.5% | 8 qtrs — |
| 24 | DIADEMA PARTNERS LP | 100.0K +100.0K (+100.0%) | 174.0K +174.0K (+100.0%) | 0.19% +0.192 pp | 0.03% +0.030 pp | USD1.74 +0.0% | 1 qtrs NEW |
| 25 | MARSHALL WACE, LLP | 82.3K +82.3K (+100.0%) | 143.3K +143.3K (+100.0%) | 0.16% +0.158 pp | 0.00% +0.000 pp | USD1.74 +0.0% | 1 qtrs NEW |
| 26 | ADAR1 CAPITAL MANAGEMENT, LLC | 75.5K +75.5K (+100.0%) | 131.4K +131.4K (+100.0%) | 0.14% +0.145 pp | 0.01% +0.010 pp | USD1.74 +0.0% | 1 qtrs NEW |
| 27 | TWO SIGMA ADVISERS, LP | 73.7K -35.0K (-32.2%) | 128.2K -126.1K (-49.6%) | 0.14% -0.139 pp | 0.00% 0.000 pp | USD2.34 -25.6% | 2 qtrs — |
| 28 | GREEN ALPHA ADVISORS, LLC | 72.1K +24.0K (+49.9%) | 125.4K +12.9K (+11.5%) | 0.14% +0.014 pp | 0.11% +0.006 pp | USD5.51 -68.4% | 8 qtrs — |
| 29 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 71.3K -106.1K (-59.8%) | 124.1K -291.1K (-70.1%) | 0.14% -0.320 pp | 0.00% +0.000 pp | USD2.26 -23.0% | 8 qtrs — |
| 30 | BANK OF AMERICA CORP /DE/ | 65.8K -570.3K (-89.7%) | 114.5K -1.4M (-92.3%) | 0.13% -1.512 pp | 0.00% 0.000 pp | USD2.11 -17.5% | 8 qtrs — |
| 31 | JANE STREET GROUP, LLC | 58.4K +26.3K (+81.9%) | 101.6K +26.5K (+35.2%) | 0.11% +0.029 pp | 0.00% +0.000 pp | USD2.75 -36.7% | 8 qtrs — |
| 32 | HUDSON BAY CAPITAL MANAGEMENT LP | 50.7K +50.7K (+100.0%) | 88.2K +88.2K (+100.0%) | 0.10% +0.097 pp | 0.00% +0.000 pp | USD1.74 +0.0% | 1 qtrs NEW |
| 33 | CIBC PRIVATE WEALTH GROUP, LLC | 50.0K +50.0K (+357,042.9%) | 87.0K +87.0K (+263,536.4%) | 0.10% +0.096 pp | 0.00% +0.000 pp | USD1.74 +0.0% | 4 qtrs — |
| 34 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 48.9K +46.5K (+1,929.4%) | 85.2K +79.5K (+1,409.0%) | 0.09% +0.088 pp | 0.02% +0.017 pp | USD1.75 -0.6% | 4 qtrs — |
| 35 | CITADEL ADVISORS LLC | 44.9K +33.8K (+304.5%) | 78.1K +52.2K (+200.8%) | 0.09% +0.058 pp | 0.00% +0.000 pp | USD4.08 -57.4% | 8 qtrs — |
| 36 | VIRTU FINANCIAL LLC | 44.0K +44.0K (+100.0%) | 77.0K +77.0K (+100.0%) | 0.08% +0.084 pp | 0.00% +0.003 pp | USD1.74 +0.0% | 3 qtrs — |
| 37 | QUADRATURE CAPITAL LTD | 37.2K +107.0 (+0.3%) | 64.8K -22.1K (-25.4%) | 0.07% -0.024 pp | 0.00% 0.000 pp | USD2.34 -25.6% | 2 qtrs — |
| 38 | CONCURRENT INVESTMENT ADVISORS, LLC | 36.0K -20.0K (-35.7%) | 62.7K -68.4K (-52.2%) | 0.07% -0.075 pp | 0.00% -0.002 pp | USD1.64 +6.1% | 4 qtrs — |
| 39 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 30.6K +30.6K (+100.0%) | 53.2K +53.2K (+100.0%) | 0.06% +0.059 pp | 0.00% +0.002 pp | USD1.74 +0.0% | 1 qtrs NEW |
| 40 | WOLVERINE ASSET MANAGEMENT LLC | 30.5K +30.5K (+100.0%) | 53.1K +53.1K (+100.0%) | 0.06% +0.059 pp | 0.00% +0.000 pp | USD1.74 +0.0% | 1 qtrs NEW |
| 41 | GOLDMAN SACHS GROUP INC | 27.3K -26.4K (-49.2%) | 47.5K -78.2K (-62.2%) | 0.05% -0.086 pp | 0.00% +0.000 pp | USD3.18 -45.3% | 7 qtrs — |
| 42 | GREENWICH WEALTH MANAGEMENT LLC | 24.0K +3.6K (+17.6%) | 42.0K -6.0K (-12.5%) | 0.05% -0.007 pp | 0.00% -0.001 pp | USD2.25 -22.7% | 2 qtrs — |
| 43 | BAADER BANK AKTIENGESELLSCHAFT | 36.8K +36.8K (+100.0%) | 39.5K +39.5K (+100.0%) | 0.07% +0.071 pp | 0.00% +0.003 pp | USD1.74 +0.0% | 1 qtrs NEW |
| 44 | LPL FINANCIAL LLC | 18.6K -7.4K (-28.4%) | 32.4K -28.4K (-46.8%) | 0.04% -0.031 pp | 0.00% +0.000 pp | USD1.95 -10.8% | 4 qtrs — |
| 45 | PRIME CAPITAL INVESTMENT ADVISORS, LLC | 18.0K -428.0 (-2.3%) | 31.4K -11.8K (-27.4%) | 0.03% -0.013 pp | 0.00% 0.000 pp | USD1.83 -4.9% | 7 qtrs — |
| 46 | BANK OF MONTREAL /CAN/ | 17.4K +— (+0.0%) | 30.2K -10.4K (-25.6%) | 0.03% -0.011 pp | 0.00% +0.000 pp | USD1.79 -2.8% | 5 qtrs — |
| 47 | RAYMOND JAMES FINANCIAL INC | 16.7K +8.0 (+0.0%) | 29.0K -10.0K (-25.6%) | 0.03% -0.011 pp | 0.00% +0.000 pp | USD2.33 -25.3% | 3 qtrs — |
| 48 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 179.00 +178.0 (+17,800.0%) | 29.0K +29.0K (+1,451,050.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.74 +0.0% | 8 qtrs — |
| 49 | STEPHENS INC /AR/ | 15.5K +2.0K (+14.8%) | 27.0K -4.6K (-14.6%) | 0.03% -0.005 pp | 0.00% 0.000 pp | USD2.26 -23.0% | 2 qtrs — |
| 50 | MAYFLOWER FINANCIAL ADVISORS, LLC | 12.6K +12.6K (+100.0%) | 21.9K +21.9K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.003 pp | USD1.74 +0.0% | 1 qtrs NEW |
| 51 | MCF ADVISORS LLC | 11.3K +— (+0.0%) | 19.6K -6.8K (-25.6%) | 0.02% -0.007 pp | 0.00% -0.001 pp | USD2.34 -25.6% | 2 qtrs — |
| 52 | HIGHTOWER ADVISORS, LLC | 11.1K +11.1K (+100.0%) | 19.4K +19.4K (+100.0%) | 0.02% +0.021 pp | 0.00% +0.000 pp | USD1.74 +0.0% | 1 qtrs NEW |
| 53 | SIGNATURE ESTATE & INVESTMENT ADVISORS LLC | 11.0K +— (+0.0%) | 19.2K -6.6K (-25.6%) | 0.02% -0.007 pp | 0.00% 0.000 pp | USD8.52 -79.6% | 7 qtrs — |
| 54 | COVESTOR LTD | 5.7K +— (+0.0%) | 10.0K -3.0K (-23.1%) | 0.01% -0.004 pp | 0.01% -0.002 pp | USD2.62 -33.6% | 8 qtrs — |
| 55 | SBI SECURITIES CO., LTD. | 4.3K -43.0 (-1.0%) | 7.4K -2.7K (-26.4%) | 0.01% -0.003 pp | 0.00% 0.000 pp | USD1.84 -5.4% | 5 qtrs — |
| 56 | WELLS FARGO & COMPANY/MN | 2.7K +2.5K (+1,170.4%) | 4.8K +4.3K (+845.5%) | 0.01% +0.005 pp | 0.00% +0.000 pp | USD2.08 -16.3% | 8 qtrs — |
| 57 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 2.0K +— (+0.0%) | 3.5K -1.2K (-25.7%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD2.34 -25.6% | 2 qtrs — |
| 58 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 1.8K +— (+0.0%) | 3.2K -1.1K (-25.6%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD13.12 -86.7% | 8 qtrs — |
| 59 | ROYAL BANK OF CANADA | 1.7K -163.8K (-99.0%) | 3.0K -384.0K (-99.2%) | 0.00% -0.423 pp | 0.00% 0.000 pp | USD2.18 -20.2% | 8 qtrs — |
| 60 | FEDERATED HERMES, INC. | 1.7K -623.0 (-26.6%) | 3.0K -2.5K (-45.4%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD1.77 -1.7% | 5 qtrs — |
| 61 | ACTIVEST WEALTH MANAGEMENT | 1.5K +— (+0.0%) | 2.6K -900.0 (-25.6%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD8.61 -79.8% | 7 qtrs — |
| 62 | LEGACY WEALTH MANAGMENT, LLC/ID | 1.4K +— (+0.0%) | 2.4K -814.0 (-25.6%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD2.34 -25.6% | 2 qtrs — |
| 63 | ADVISOR GROUP HOLDINGS, INC. | 966.00 -941.0 (-49.3%) | 1.7K -2.8K (-62.8%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD6.31 -72.4% | 8 qtrs — |
| 64 | PNC FINANCIAL SERVICES GROUP, INC. | 885.00 -150.0 (-14.5%) | 1.5K -882.0 (-36.4%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD2.84 -38.7% | 8 qtrs — |
| 65 | MAI CAPITAL MANAGEMENT | 830.00 -99.0 (-10.7%) | 1.4K -729.0 (-33.5%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD1.83 -4.9% | 5 qtrs — |
| 66 | BARCLAYS PLC | 722.00 -33.3K (-97.9%) | 1.3K -195.3K (-99.4%) | 0.00% -0.086 pp | 0.00% 0.000 pp | USD2.35 -26.0% | 7 qtrs — |
| 67 | RHUMBLINE ADVISERS | 602.00 +— (+0.0%) | 1.0K -361.0 (-25.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD8.07 -78.4% | 8 qtrs — |
| 68 | CLEARSTEAD ADVISORS, LLC | 500.00 +— (+0.0%) | 870.00 -300.0 (-25.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD8.61 -79.8% | 7 qtrs — |
| 69 | NEWBRIDGE FINANCIAL SERVICES GROUP, INC. | 359.00 +— (+0.0%) | 624.00 -215.0 (-25.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD12.32 -85.9% | 8 qtrs — |
| 70 | BNP PARIBAS ARBITRAGE, SNC | 352.00 -10.6K (-96.8%) | 612.00 -25.1K (-97.6%) | 0.00% -0.028 pp | 0.00% +0.000 pp | USD3.09 -43.7% | 8 qtrs — |
| 71 | MJT & ASSOCIATES FINANCIAL ADVISORY GROUP, INC. | 325.00 +— (+0.0%) | 566.00 -195.0 (-25.6%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD1.63 +6.7% | 4 qtrs — |
| 72 | JONES FINANCIAL COMPANIES LLLP | 240.00 -6.0 (-2.4%) | 418.00 -192.0 (-31.5%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.50 -30.4% | 7 qtrs — |
| 73 | ROOT FINANCIAL PARTNERS, LLC | 208.00 +— (+0.0%) | 362.00 -125.0 (-25.7%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.34 -25.6% | 2 qtrs — |
| 74 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 141.00 +— (+0.0%) | 245.00 -85.0 (-25.8%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD13.11 -86.7% | 8 qtrs — |
| 75 | SRS CAPITAL ADVISORS, INC. | 103.00 +— (+0.0%) | 179.00 -62.0 (-25.7%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.34 -25.6% | 2 qtrs — |
| 76 | NATIONAL BANK OF CANADA /FI/ | 99.00 +58.0 (+141.5%) | 172.00 +76.0 (+79.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.23 -72.1% | 8 qtrs — |
| 77 | SMARTLEAF ASSET MANAGEMENT LLC | 83.00 +83.0 (+100.0%) | 146.00 +146.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.73 +0.6% | 1 qtrs NEW |
| 78 | BLUME CAPITAL MANAGEMENT, INC. | 83.00 +— (+0.0%) | 145.00 -50.0 (-25.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD13.11 -86.7% | 8 qtrs — |
| 79 | PITTENGER & ANDERSON INC | 77.00 +— (+0.0%) | 134.00 -47.0 (-26.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD13.12 -86.7% | 8 qtrs — |
| 80 | AMERITAS INVESTMENT PARTNERS, INC. | 64.00 +— (+0.0%) | 111.00 -39.0 (-26.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.33 -25.3% | 7 qtrs — |
| 81 | ALLWORTH FINANCIAL LP | 47.00 -257.0 (-84.5%) | 82.00 -630.0 (-88.5%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD8.60 -79.8% | 8 qtrs — |
| 82 | JPMORGAN CHASE & CO | 42.00 -65.2K (-99.9%) | 73.00 -152.5K (-100.0%) | 0.00% -0.168 pp | 0.00% +0.000 pp | USD2.55 -31.8% | 8 qtrs — |
| 83 | PINNACLE WEALTH PLANNING SERVICES, INC. | 41.00 +41.0 (+100.0%) | 71.00 +71.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.73 +0.6% | 1 qtrs NEW |
| 84 | 1 NORTH WEALTH SERVICES LLC | 41.00 +— (+0.0%) | 71.00 -25.0 (-26.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.61 +8.1% | 4 qtrs — |
| 85 | TD WATERHOUSE CANADA INC. | 41.00 +— (+0.0%) | 71.00 -26.0 (-26.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.59 -79.7% | 7 qtrs — |
| 86 | INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | 36.00 +36.0 (+100.0%) | 63.00 +63.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.72 +1.2% | 1 qtrs NEW |
| 87 | ATWOOD & PALMER INC | 18.00 +— (+0.0%) | 32.00 -11.0 (-25.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD13.11 -86.7% | 8 qtrs — |
| 88 | FARTHER FINANCE ADVISORS, LLC | 16.00 +— (+0.0%) | 28.00 -9.0 (-24.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.75 +132.0% | 9 qtrs — |
| 89 | CORECAP ADVISORS, LLC | 16.00 +— (+0.0%) | 28.00 -9.0 (-24.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.69 +3.0% | 8 qtrs — |
| 90 | KEY FINANCIAL INC | 14.00 +— (+0.0%) | 24.00 -9.0 (-27.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 -13.0% | 3 qtrs — |
| 91 | IFP ADVISORS, INC | 14.00 +— (+0.0%) | 24.00 -9.0 (-27.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 -13.0% | 3 qtrs — |
| 92 | THOMPSON INVESTMENT MANAGEMENT, INC. | 13.00 +— (+0.0%) | 23.00 -7.0 (-23.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD13.08 -86.7% | 8 qtrs — |
| 93 | GOLDEN STATE WEALTH MANAGEMENT, LLC | 10.00 +— (+0.0%) | 17.00 -6.0 (-26.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.80 -3.3% | 5 qtrs — |
| 94 | NORTH STAR INVESTMENT MANAGEMENT CORP. | 7.00 +— (+0.0%) | 12.00 -4.0 (-25.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD13.00 -86.6% | 8 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 13 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.45% | 98.8K | 0.20% |
| 2 | iShares Micro-Cap ETF IWC | 0.02% | 330.6K | 0.60% |
| 3 | Vanguard Extended Market ETF VXF | 0.00% | 942.5K | 0.05% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 1.5K | 0.17% |
| 5 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 7.2K | 0.03% |
| 6 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 19.8K | 0.17% |
| 7 | Vanguard Total Stock Market ETF VTI | 0.00% | 3.39M | 0.03% |
| 8 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 7.4K | 0.22% |
| 9 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 4.0K | 0.22% |
| 10 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 1.6K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
3.00
Bullish
Buys
18
Sells
18
Shares acquired
444.5K
Shares disposed
138.1K
Cash buys
—
Cash sales
—
Net activity
+306,403
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Sumner Michael John | Officer | M-Exempt | A | Common Stock | 4,292 | 0.00 | — | 34,799 | D | ↗ |
| 2026-03-04 | Sumner Michael John | Officer | A-Award | A | Restricted Stock Unit | 29,608 | 0.00 | — | 29,608 | D | ↗ |
| 2026-03-04 | Shea Jacqueline Elizabeth | Director / Officer | A-Award | A | Restricted Stock Unit | 78,760 | 0.00 | — | 78,760 | D | ↗ |
| 2026-03-04 | KIES PETER | Officer | A-Award | A | Common Stock Option | 31,240 | 1.73 | 54.0K | 31,240 | D | ↗ |
| 2026-03-04 | Humeau Laurent | Officer | A-Award | A | Restricted Stock Unit | 21,560 | 0.00 | — | 21,560 | D | ↗ |
| 2026-02-26 | Weiner David B. | Director | M-Exempt | D | Restricted Stock Unit | 972 | 0.00 | — | 0 | D | ↗ |
| 2026-02-26 | Sumner Michael John | Officer | M-Exempt | D | Restricted Stock Unit | 5,010 | 0.00 | — | 5,009 | D | ↗ |
| 2026-02-26 | Shea Jacqueline Elizabeth | Director / Officer | M-Exempt | A | Common Stock | 28,401 | 0.00 | — | 98,661 | D | ↗ |
| 2026-02-26 | KIES PETER | Officer | M-Exempt | D | Restricted Stock Unit | 5,010 | 0.00 | — | 5,009 | D | ↗ |
| 2026-02-26 | Humeau Laurent | Officer | M-Exempt | D | Restricted Stock Unit | 5,010 | 0.00 | — | 5,009 | D | ↗ |
| 2025-06-30 | Sumner Michael John | Officer | M-Exempt | A | Common Stock | 2,916 | 0.00 | — | 17,850 | D | ↗ |
| 2025-05-21 | Zoth Lota S. | Director | M-Exempt | D | Restricted Stock Unit | 2,167 | 0.00 | — | 0 | D | ↗ |
| 2025-05-21 | YARNO WENDY L | Director | M-Exempt | D | Restricted Stock Unit | 2,167 | 0.00 | — | 0 | D | ↗ |
| 2025-05-21 | Weiner David B. | Director | M-Exempt | D | Restricted Stock Unit | 2,167 | 0.00 | — | 0 | D | ↗ |
| 2025-05-21 | Shepard Jay | Director | M-Exempt | D | Restricted Stock Unit | 2,167 | 0.00 | — | 0 | D | ↗ |
| 2025-05-21 | Miller Ann Calby | Director | M-Exempt | D | Restricted Stock Unit | 2,167 | 0.00 | — | 0 | D | ↗ |
| 2025-05-21 | DANSEY ROGER D | Director | M-Exempt | A | Common Stock | 2,167 | 0.00 | — | 8,916 | D | ↗ |
| 2025-05-21 | BENITO SIMON X | Director | M-Exempt | D | Restricted Stock Unit | 2,167 | 0.00 | — | 0 | D | ↗ |
| 2025-05-20 | Sumner Michael John | Officer | A-Award | A | Common Stock Option | 35,100 | 2.13 | 74.8K | 35,100 | D | ↗ |
| 2025-05-20 | Shea Jacqueline Elizabeth | Director / Officer | A-Award | A | Restricted Stock Unit | 84,888 | 0.00 | — | 84,888 | D | ↗ |
| 2025-05-20 | KIES PETER | Officer | A-Award | A | Restricted Stock Unit | 26,100 | 0.00 | — | 26,100 | D | ↗ |
| 2025-05-20 | Humeau Laurent | Officer | A-Award | A | Restricted Stock Unit | 18,081 | 0.00 | — | 18,081 | D | ↗ |
| 2025-05-15 | Sumner Michael John | Officer | M-Exempt | D | Restricted Stock Unit | 2,385 | 0.00 | — | 2,385 | D | ↗ |
| 2025-05-15 | Shea Jacqueline Elizabeth | Director / Officer | M-Exempt | D | Restricted Stock Unit | 17,744 | 0.00 | — | 17,744 | D | ↗ |
| 2025-05-15 | KIES PETER | Officer | M-Exempt | D | Restricted Stock Unit | 4,771 | 0.00 | — | 4,771 | D | ↗ |
| 2025-05-15 | Humeau Laurent | Officer | M-Exempt | D | Restricted Stock Unit | 4,771 | 0.00 | — | 4,771 | D | ↗ |
| 2025-05-10 | Shea Jacqueline Elizabeth | Director / Officer | M-Exempt | A | Common Stock | 5,500 | 0.00 | — | 52,050 | D | ↗ |
| 2025-02-27 | Sumner Michael John | Officer | A-Award | A | Restricted Stock Unit | 34,650 | 0.00 | — | 34,650 | D | ↗ |
| 2025-02-27 | Shea Jacqueline Elizabeth | Director / Officer | A-Award | A | Restricted Stock Unit | 85,201 | 0.00 | — | 85,201 | D | ↗ |
| 2025-02-27 | KIES PETER | Officer | A-Award | A | Restricted Stock Unit | 31,900 | 0.00 | — | 31,900 | D | ↗ |
| 2025-02-27 | Humeau Laurent | Officer | A-Award | A | Restricted Stock Unit | 22,098 | 0.00 | — | 22,098 | D | ↗ |
| 2025-02-26 | Weiner David B. | Director | M-Exempt | D | Restricted Stock Unit | 972 | 0.00 | — | 0 | D | ↗ |
| 2025-02-26 | Sumner Michael John | Officer | M-Exempt | A | Common Stock | 5,010 | 0.00 | — | 13,229 | D | ↗ |
| 2025-02-26 | Shea Jacqueline Elizabeth | Director / Officer | M-Exempt | D | Restricted Stock Unit | 5,852 | 0.00 | — | 0 | D | ↗ |
| 2025-02-26 | KIES PETER | Officer | M-Exempt | D | Restricted Stock Unit | 3,997 | 0.00 | — | 0 | D | ↗ |
| 2025-02-26 | Humeau Laurent | Officer | M-Exempt | D | Restricted Stock Unit | 5,010 | 0.00 | — | 10,019 | D | ↗ |
| 2024-12-18 | Sumner Michael John | Officer | A-Award | A | Common Stock Option | 5,708 | 1.78 | 10.2K | 5,708 | D | ↗ |
| 2024-06-30 | Sumner Michael John | Officer | M-Exempt | A | Common Stock | 2,917 | 0.00 | — | 8,219 | — | ↗ |
| 2024-05-21 | Zoth Lota S. | Director | A-Award | A | Restricted Stock Unit | 2,167 | 0.00 | — | 2,167 | — | ↗ |
| 2024-05-21 | YARNO WENDY L | Director | A-Award | A | Restricted Stock Unit | 2,167 | 0.00 | — | 2,167 | — | ↗ |
| 2024-05-21 | Weiner David B. | Director | A-Award | A | Common Stock Options | 2,917 | 10.99 | 32.1K | 2,917 | — | ↗ |
| 2024-05-21 | Shepard Jay | Director | A-Award | A | Restricted Stock Unit | 2,167 | 0.00 | — | 2,167 | — | ↗ |
| 2024-05-21 | Miller Ann Calby | Director | A-Award | A | Restricted Stock Unit | 2,167 | 0.00 | — | 2,167 | — | ↗ |
| 2024-05-21 | DANSEY ROGER D | Director | A-Award | A | Common Stock Options | 2,917 | 10.99 | 32.1K | 2,917 | — | ↗ |
| 2024-05-21 | BENITO SIMON X | Director | A-Award | A | Restricted Stock Unit | 2,167 | 0.00 | — | 2,167 | — | ↗ |
| 2024-05-15 | Zoth Lota S. | Director | M-Exempt | D | Restricted Stock Unit | 2,166 | 0.00 | — | 0 | — | ↗ |
| 2024-05-15 | YARNO WENDY L | Director | M-Exempt | A | Common Stock | 2,166 | 0.00 | — | 8,345 | — | ↗ |
| 2024-05-15 | Weiner David B. | Director | M-Exempt | A | Common Stock | 2,166 | 0.00 | — | 82,509 | — | ↗ |
| 2024-05-15 | Sumner Michael John | Officer | M-Exempt | A | Common Stock | 2,386 | 0.00 | — | 5,302 | — | ↗ |
| 2024-05-15 | Shepard Jay | Director | M-Exempt | D | Restricted Stock Unit | 2,166 | 0.00 | — | 0 | — | ↗ |
| 2024-05-15 | Shea Jacqueline Elizabeth | Director / Officer | M-Exempt | A | Common Stock | 17,745 | 0.00 | — | 41,365 | — | ↗ |
| 2024-05-15 | Miller Ann Calby | Director | M-Exempt | D | Restricted Stock Unit | 2,166 | 0.00 | — | 0 | — | ↗ |
| 2024-05-15 | KIES PETER | Officer | M-Exempt | D | Restricted Stock Unit | 4,771 | 0.00 | — | 9,542 | — | ↗ |
| 2024-05-15 | Humeau Laurent | Officer | M-Exempt | D | Restricted Stock Unit | 4,771 | 0.00 | — | 9,542 | — | ↗ |
| 2024-05-15 | DANSEY ROGER D | Director | M-Exempt | D | Restricted Stock Unit | 2,166 | 0.00 | — | 0 | — | ↗ |
| 2024-05-15 | BENITO SIMON X | Director | M-Exempt | D | Restricted Stock Unit | 2,166 | 0.00 | — | 0 | — | ↗ |
| 2024-05-13 | DANSEY ROGER D | Director | M-Exempt | A | Common Stock | 1,000 | 0.00 | — | 4,583 | — | ↗ |
| 2024-05-10 | Shea Jacqueline Elizabeth | Director / Officer | F-InKind | D | Common Stock | 2,392 | 10.65 | 25.5K | 23,620 | — | ↗ |
| 2024-02-28 | Sumner Michael John | Officer | A-Award | A | Restricted Stock Unit | 15,029 | 0.00 | — | 15,029 | — | ↗ |
| 2024-02-28 | Shea Jacqueline Elizabeth | Director / Officer | A-Award | A | Common Stock Option | 69,733 | 8.46 | 589.9K | 69,733 | — | ↗ |
| 2024-02-28 | Humeau Laurent | Officer | A-Award | A | Restricted Stock Unit | 15,029 | 0.00 | — | 15,029 | — | ↗ |
| 2024-02-26 | Weiner David B. | Director | M-Exempt | D | Restricted Stock Unit | 972 | 0.00 | — | 0 | — | ↗ |
| 2024-02-26 | Shea Jacqueline Elizabeth | Director / Officer | M-Exempt | D | Restricted Stock Unit | 5,853 | 0.00 | — | 5,852 | — | ↗ |
| 2024-02-26 | Humeau Laurent | Officer | M-Exempt | D | Restricted Stock Unit | 1,878 | 0.00 | — | 0 | — | ↗ |
| 2023-06-30 | Sumner Michael John | Officer | M-Exempt | A | Common Stock | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2023-06-05 | Zoth Lota S. | Director | S-Sale | D | Common Stock | 5,700 | 0.56 | 3.2K | 52,716 | — | ↗ |
| 2023-05-16 | Zoth Lota S. | Director | M-Exempt | D | Restricted Stock Unit | 19,000 | 0.00 | — | 0 | — | ↗ |
| 2023-05-16 | YARNO WENDY L | Director | M-Exempt | D | Restricted Stock Unit | 19,000 | 0.00 | — | 0 | — | ↗ |
| 2023-05-16 | Weiner David B. | Director | M-Exempt | D | Restricted Stock Unit | 19,000 | 0.00 | — | 0 | — | ↗ |
| 2023-05-16 | Shepard Jay | Director | M-Exempt | A | Common Stock | 19,000 | 0.00 | — | 58,521 | — | ↗ |
| 2023-05-16 | Miller Ann Calby | Director | M-Exempt | D | Restricted Stock Unit | 19,000 | 0.00 | — | 0 | — | ↗ |
| 2023-05-16 | DANSEY ROGER D | Director | M-Exempt | D | Restricted Stock Unit | 19,000 | 0.00 | — | 0 | — | ↗ |
| 2023-05-16 | BENITO SIMON X | Director | M-Exempt | D | Restricted Stock Unit | 19,000 | 0.00 | — | 0 | — | ↗ |
| 2023-05-15 | Zoth Lota S. | Director | A-Award | A | Common Stock Options | 35,000 | 0.77 | 27.0K | 35,000 | — | ↗ |
| 2023-05-15 | YARNO WENDY L | Director | A-Award | A | Restricted Stock Unit | 26,000 | 0.00 | — | 26,000 | — | ↗ |
| 2023-05-15 | Weiner David B. | Director | A-Award | A | Restricted Stock Unit | 26,000 | 0.00 | — | 26,000 | — | ↗ |
| 2023-05-15 | Sumner Michael John | Officer | A-Award | A | Restricted Stock Unit | 85,878 | 0.00 | — | 85,878 | — | ↗ |
| 2023-05-15 | Shepard Jay | Director | A-Award | A | Restricted Stock Unit | 26,000 | 0.00 | — | 26,000 | — | ↗ |
| 2023-05-15 | Shea Jacqueline Elizabeth | Director / Officer | A-Award | A | Restricted Stock Unit | 638,800 | 0.00 | — | 638,800 | — | ↗ |
| 2023-05-15 | Miller Ann Calby | Director | A-Award | A | Restricted Stock Unit | 26,000 | 0.00 | — | 26,000 | — | ↗ |
| 2023-05-15 | KIES PETER | Officer | A-Award | A | Restricted Stock Unit | 171,756 | 0.00 | — | 171,756 | — | ↗ |
| 2023-05-15 | Humeau Laurent | Officer | A-Award | A | Restricted Stock Unit | 171,756 | 0.00 | — | 171,756 | — | ↗ |
| 2023-05-15 | DANSEY ROGER D | Director | A-Award | A | Restricted Stock Unit | 26,000 | 0.00 | — | 26,000 | — | ↗ |
| 2023-05-15 | BENITO SIMON X | Director | A-Award | A | Restricted Stock Unit | 26,000 | 0.00 | — | 26,000 | — | ↗ |
| 2023-05-13 | DANSEY ROGER D | Director | M-Exempt | D | Restricted Stock Unit | 12,000 | 0.00 | — | 12,000 | — | ↗ |
| 2023-05-10 | Shea Jacqueline Elizabeth | Director / Officer | M-Exempt | A | Common Stock | 66,000 | 0.00 | — | 226,817 | — | ↗ |
| 2023-03-13 | Weiner David B. | Director | S-Sale | D | Common Stock | 5,833 | 1.15 | 6.7K | 910,124 | — | ↗ |
| 2023-03-11 | Weiner David B. | Director | M-Exempt | D | Restricted Stock Unit | 11,666 | 0.00 | — | 0 | — | ↗ |
| 2023-03-11 | Shea Jacqueline Elizabeth | Director / Officer | M-Exempt | A | Common Stock | 59,737 | 0.00 | — | 186,797 | — | ↗ |
| 2023-03-11 | KIES PETER | Officer | M-Exempt | D | Restricted Stock Unit | 59,737 | 0.00 | — | 0 | — | ↗ |
| 2023-03-11 | Humeau Laurent | Officer | F-InKind | D | Common Stock | 20,658 | 1.13 | 23.3K | 214,637 | — | ↗ |
| 2023-02-27 | Weiner David B. | Director | A-Award | A | Common Stock Option | 60,000 | 1.24 | 74.4K | 60,000 | — | ↗ |
| 2023-02-27 | Sumner Michael John | Officer | A-Award | A | Common Stock Option | 112,500 | 1.24 | 139.5K | 112,500 | — | ↗ |
| 2023-02-27 | Shea Jacqueline Elizabeth | Director / Officer | A-Award | A | Common Stock Option | 836,800 | 1.24 | 1.04M | 836,800 | — | ↗ |
| 2023-02-27 | KIES PETER | Officer | A-Award | A | Common Stock Option | 225,000 | 1.24 | 279.0K | 225,000 | — | ↗ |
| 2023-02-27 | Humeau Laurent | Officer | A-Award | A | Common Stock Option | 225,000 | 1.24 | 279.0K | 225,000 | — | ↗ |
| 2023-02-26 | Weiner David B. | Director | M-Exempt | D | Restricted Stock Unit | 11,667 | 0.00 | — | 11,666 | — | ↗ |
| 2023-02-26 | Shea Jacqueline Elizabeth | Director / Officer | F-InKind | D | Common Stock | 9,788 | 1.28 | 12.5K | 89,311 | — | ↗ |
| 2023-02-26 | KIES PETER | Officer | M-Exempt | A | Common Stock | 22,544 | 0.00 | — | 201,828 | — | ↗ |
| 2023-02-26 | Humeau Laurent | Officer | M-Exempt | D | Restricted Stock Unit | 22,544 | 0.00 | — | 22,544 | — | ↗ |
| 2023-01-15 | Shepard Jay | Director | M-Exempt | A | Common Stock | 4,273 | 0.00 | — | 39,521 | — | ↗ |
| 2022-08-11 | Weiner David B. | Director | M-Exempt | D | Common Stock Option | 11,875 | 0.00 | — | 11,875 | — | ↗ |
| 2022-07-20 | BENITO SIMON X | Director | M-Exempt | A | Common Stock | 2,000 | 2.20 | 4.4K | 77,305 | — | ↗ |
| 2022-06-30 | Sumner Michael John | Officer | A-Award | A | Restricted Stock Unit | 105,000 | 0.00 | — | 105,000 | — | ↗ |
| 2022-06-27 | Sumner Michael John | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-05-16 | YARNO WENDY L | Director | A-Award | A | Common Stock Options | 28,000 | 1.89 | 52.9K | 28,000 | — | ↗ |
| 2022-05-16 | Weiner David B. | Director | A-Award | A | Common Stock Options | 28,000 | 1.89 | 52.9K | 28,000 | — | ↗ |
| 2022-05-16 | Shepard Jay | Director | A-Award | A | Restricted Stock Unit | 19,000 | 0.00 | — | 19,000 | — | ↗ |
| 2022-05-16 | Miller Ann Calby | Director | A-Award | A | Common Stock Options | 28,000 | 1.89 | 52.9K | 28,000 | — | ↗ |
| 2022-05-16 | BENITO SIMON X | Director | A-Award | A | Restricted Stock Unit | 19,000 | 0.00 | — | 19,000 | — | ↗ |
| 2022-05-13 | Zoth Lota S. | Director | M-Exempt | D | Restricted Stock Unit | 18,000 | 0.00 | — | 0 | — | ↗ |
| 2022-05-13 | YARNO WENDY L | Director | M-Exempt | A | Common Stock | 18,000 | 0.00 | — | 55,153 | — | ↗ |
| 2022-05-13 | Weiner David B. | Director | M-Exempt | D | Restricted Stock Unit | 18,000 | 0.00 | — | 0 | — | ↗ |
| 2022-05-13 | Shepard Jay | Director | M-Exempt | D | Restricted Stock Unit | 18,000 | 0.00 | — | 0 | — | ↗ |
| 2022-05-13 | Miller Ann Calby | Director | A-Award | A | Restricted Stock Unit | 19,000 | 0.00 | — | 19,000 | — | ↗ |
| 2022-05-13 | DANSEY ROGER D | Director | A-Award | A | Restricted Stock Unit | 19,000 | 0.00 | — | 19,000 | — | ↗ |
| 2022-05-13 | BENITO SIMON X | Director | M-Exempt | A | Common Stock | 18,000 | 0.00 | — | 75,305 | — | ↗ |
| 2022-05-10 | Shea Jacqueline Elizabeth | Officer | A-Award | A | Common Stock Option | 309,400 | 0.00 | — | 309,400 | — | ↗ |
| 2022-03-25 | Shea Jacqueline Elizabeth | Officer | F-InKind | D | Common Stock | 7,247 | 3.63 | 26.3K | 76,555 | — | ↗ |
| 2022-03-21 | Miller Ann Calby | Director | M-Exempt | A | Common Stock | 4,273 | 0.00 | — | 29,534 | — | ↗ |
| 2022-03-16 | BENITO SIMON X | Director | M-Exempt | A | Common Stock | 2,000 | 2.20 | 4.4K | 59,305 | — | ↗ |
| 2022-03-11 | Weiner David B. | Director | M-Exempt | D | Restricted Stock Unit | 11,667 | 0.00 | — | 11,666 | — | ↗ |
| 2022-03-11 | Shea Jacqueline Elizabeth | Officer | F-InKind | D | Common Stock | 25,974 | 3.22 | 83.6K | 67,136 | — | ↗ |
| 2022-03-11 | Kim Jong Joseph | Director / Officer | M-Exempt | D | Restricted Stock Unit | 139,387 | 0.00 | — | 139,386 | — | ↗ |
| 2022-03-11 | KIES PETER | Officer | M-Exempt | D | Restricted Stock Unit | 59,737 | 0.00 | — | 59,737 | — | ↗ |
| 2022-03-11 | Humeau Laurent | Officer | M-Exempt | D | Restricted Stock Unit | 59,737 | 0.00 | — | 59,737 | D | ↗ |
| 2022-03-08 | Weiner David B. | Director | M-Exempt | D | Restricted Stock Unit | 11,666 | 0.00 | — | 0 | — | ↗ |
| 2022-03-08 | Kim Jong Joseph | Officer | M-Exempt | D | Restricted Stock Unit | 63,700 | 0.00 | — | 0 | — | ↗ |
| 2022-03-08 | KIES PETER | Officer | F-InKind | D | Common Stock | 11,287 | 3.26 | 36.8K | 150,957 | — | ↗ |
| 2022-03-08 | Humeau Laurent | Officer | M-Exempt | D | Restricted Stock Unit | 19,900 | 0.00 | — | 0 | — | ↗ |
| 2022-02-26 | Weiner David B. | Director | M-Exempt | D | Restricted Stock Unit | 11,667 | 0.00 | — | 23,333 | — | ↗ |
| 2022-02-26 | Shea Jacqueline Elizabeth | Officer | F-InKind | D | Common Stock | 10,764 | 3.22 | 34.7K | 33,373 | — | ↗ |
| 2022-02-26 | Kim Jong Joseph | Director / Officer | M-Exempt | D | Restricted Stock Unit | 68,767 | 0.00 | — | 137,533 | — | ↗ |
| 2022-02-26 | KIES PETER | Officer | M-Exempt | D | Restricted Stock Unit | 22,545 | 0.00 | — | 45,088 | — | ↗ |
| 2022-02-26 | Humeau Laurent | Officer | F-InKind | D | Common Stock | 8,545 | 3.22 | 27.5K | 82,587 | — | ↗ |
| 2022-01-19 | BENITO SIMON X | Director | M-Exempt | A | Common Stock | 2,000 | 2.20 | 4.4K | 59,305 | — | ↗ |
| 2022-01-15 | Shepard Jay | Director | M-Exempt | A | Common Stock | 4,274 | 0.00 | — | 17,248 | — | ↗ |
| 2022-01-05 | Zoth Lota S. | Director | S-Sale | D | Common Stock | 961 | 5.01 | 4.8K | 25,016 | — | ↗ |
| 2022-01-03 | Zoth Lota S. | Director | M-Exempt | A | Common Stock | 4,090 | 0.00 | — | 25,977 | — | ↗ |
| 2021-08-09 | Humeau Laurent | Officer | S-Sale | D | Common Stock | 10,317 | 9.15 | 94.4K | 68,587 | — | ↗ |
| 2021-06-09 | Shea Jacqueline Elizabeth | Officer | S-Sale | D | Common Stock | 38,535 | 10.01 | 385.7K | 21,592 | — | ↗ |
| 2021-06-09 | KIES PETER | Officer | M-Exempt | A | Common Stock | 13,750 | 2.16 | 29.7K | 164,538 | — | ↗ |
| 2021-06-09 | Humeau Laurent | Officer | S-Sale | D | Common Stock | 10,318 | 9.07 | 93.6K | 78,904 | — | ↗ |
| 2021-06-03 | KIES PETER | Officer | S-Sale | D | Common Stock | 10,000 | 8.03 | 80.3K | 150,788 | — | ↗ |
| 2021-05-17 | Zoth Lota S. | Director | S-Sale | D | Common Stock | 2,045 | 6.62 | 13.5K | 21,887 | — | ↗ |
| 2021-05-17 | Weiner David B. | Director | S-Sale | D | Common Stock | 3,045 | 6.62 | 20.2K | 856,791 | — | ↗ |
| 2021-05-17 | BENITO SIMON X | Director | S-Sale | D | Common Stock | 3,045 | 6.62 | 20.2K | 57,305 | — | ↗ |
| 2021-05-14 | Zoth Lota S. | Director | M-Exempt | D | Restricted Stock Unit | 8,700 | 0.00 | — | 0 | — | ↗ |
| 2021-05-14 | YARNO WENDY L | Director | M-Exempt | A | Common Stock | 8,700 | 0.00 | — | 37,153 | — | ↗ |
| 2021-05-14 | Weiner David B. | Director | M-Exempt | D | Restricted Stock Unit | 8,700 | 0.00 | — | 0 | — | ↗ |
| 2021-05-14 | Shepard Jay | Director | M-Exempt | D | Restricted Stock Unit | 8,700 | 0.00 | — | 0 | — | ↗ |
| 2021-05-14 | Miller Ann Calby | Director | M-Exempt | D | Restricted Stock Unit | 8,700 | 0.00 | — | 0 | — | ↗ |
| 2021-05-14 | BENITO SIMON X | Director | M-Exempt | A | Common Stock | 8,700 | 0.00 | — | 60,350 | — | ↗ |
| 2021-05-13 | Zoth Lota S. | Director | A-Award | A | Common Stock Options | 27,000 | 6.23 | 168.2K | 27,000 | — | ↗ |
| 2021-05-13 | YARNO WENDY L | Director | A-Award | A | Restricted Stock Unit | 18,000 | 0.00 | — | 18,000 | — | ↗ |
| 2021-05-13 | Weiner David B. | Director | A-Award | A | Restricted Stock Unit | 18,000 | 0.00 | — | 18,000 | — | ↗ |
| 2021-05-13 | Shepard Jay | Director | A-Award | A | Restricted Stock Unit | 18,000 | 0.00 | — | 18,000 | — | ↗ |
| 2021-05-13 | Miller Ann Calby | Director | A-Award | A | Restricted Stock Unit | 18,000 | 0.00 | — | 18,000 | — | ↗ |
| 2021-05-13 | DANSEY ROGER D | Director | A-Award | A | Restricted Stock Unit | 36,000 | 0.00 | — | 36,000 | — | ↗ |
| 2021-05-13 | BENITO SIMON X | Director | A-Award | A | Restricted Stock Unit | 18,000 | 0.00 | — | 18,000 | — | ↗ |
| 2021-04-21 | Weiner David B. | Director | M-Exempt | A | Common Stock | 22,500 | 2.40 | 54.0K | 877,719 | — | ↗ |
| 2021-04-21 | KIES PETER | Officer | S-Sale | D | Common Stock | 10,000 | 8.52 | 85.2K | 160,788 | — | ↗ |
| 2021-04-16 | BENITO SIMON X | Director | M-Exempt | D | Common Stock Options | 2,000 | 3.56 | 7.1K | 0 | — | ↗ |
| 2021-03-26 | Shea Jacqueline Elizabeth | Officer | S-Sale | D | Common Stock | 4,710 | 8.97 | 42.2K | 60,127 | — | ↗ |
| 2021-03-25 | Shea Jacqueline Elizabeth | Officer | M-Exempt | A | Common Stock | 16,667 | 0.00 | — | 72,084 | — | ↗ |
| 2021-03-21 | Miller Ann Calby | Director | M-Exempt | A | Common Stock | 4,274 | 0.00 | — | 16,561 | — | ↗ |
| 2021-03-16 | BENITO SIMON X | Director | M-Exempt | A | Common Stock | 2,000 | 3.56 | 7.1K | 53,650 | — | ↗ |
| 2021-03-12 | Shea Jacqueline Elizabeth | Officer | S-Sale | D | Common Stock | 16,881 | 10.06 | 169.8K | 55,417 | — | ↗ |
| 2021-03-11 | Weiner David B. | Director | M-Exempt | D | Restricted Stock Unit | 11,667 | 0.00 | — | 23,333 | — | ↗ |
| 2021-03-11 | Shea Jacqueline Elizabeth | Officer | M-Exempt | A | Common Stock | 59,737 | 0.00 | — | 98,272 | — | ↗ |
| 2021-03-11 | Kim Jong Joseph | Director / Officer | F-InKind | D | Common Stock | 74,545 | 10.57 | 787.9K | 1,228,658 | — | ↗ |
| 2021-03-11 | KIES PETER | Officer | M-Exempt | A | Common Stock | 59,737 | 0.00 | — | 202,198 | — | ↗ |
| 2021-03-11 | Humeau Laurent | Officer | M-Exempt | A | Common Stock | 59,737 | 0.00 | — | 115,189 | — | ↗ |
| 2021-03-09 | Weiner David B. | Director | S-Sale | D | Common Stock | 3,500 | 9.60 | 33.6K | 843,552 | — | ↗ |
| 2021-03-08 | Weiner David B. | Director | M-Exempt | D | Restricted Stock Unit | 11,667 | 0.00 | — | 11,666 | — | ↗ |
| 2021-03-08 | Kim Jong Joseph | Director / Officer | F-InKind | D | Common Stock | 34,067 | 8.91 | 303.5K | 1,163,816 | — | ↗ |
| 2021-03-08 | KIES PETER | Officer | M-Exempt | D | Restricted Stock Unit | 21,467 | 0.00 | — | 21,466 | — | ↗ |
| 2021-03-08 | Humeau Laurent | Officer | M-Exempt | A | Common Stock | 19,900 | 0.00 | — | 62,334 | — | ↗ |
| 2021-03-05 | Weiner David B. | Director | M-Exempt | D | Restricted Stock Unit | 11,666 | 0.00 | — | 0 | — | ↗ |
| 2021-03-05 | Kim Jong Joseph | Director / Officer | M-Exempt | A | Common Stock | 120,100 | 0.00 | — | 1,198,413 | — | ↗ |
| 2021-03-05 | KIES PETER | Officer | M-Exempt | D | Restricted Stock Unit | 27,566 | 0.00 | — | 0 | — | ↗ |
| 2021-03-05 | Humeau Laurent | Officer | M-Exempt | D | Restricted Stock Unit | 27,566 | 0.00 | — | 0 | — | ↗ |
| 2021-02-26 | Weiner David B. | Director | A-Award | A | Restricted Stock Unit | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2021-02-26 | Shea Jacqueline Elizabeth | Officer | A-Award | A | Common Stock Option | 104,833 | 11.10 | 1.16M | 104,833 | — | ↗ |
| 2021-02-26 | Kim Jong Joseph | Director / Officer | A-Award | A | Common Stock Option | 319,800 | 11.10 | 3.55M | 319,800 | — | ↗ |
| 2021-02-26 | KIES PETER | Officer | A-Award | A | Restricted Stock Unit | 67,633 | 0.00 | — | 67,633 | — | ↗ |
| 2021-02-26 | Humeau Laurent | Officer | A-Award | A | Restricted Stock Unit | 67,633 | 0.00 | — | 67,633 | — | ↗ |
| 2021-02-16 | BENITO SIMON X | Director | S-Sale | D | Common Stock | 2,000 | 14.68 | 29.4K | 51,650 | — | ↗ |
| 2021-02-03 | Kim Jong Joseph | Director / Officer | M-Exempt | A | Common Stock | 62,500 | 4.56 | 285.0K | 1,140,813 | — | ↗ |
| 2021-02-01 | Shea Jacqueline Elizabeth | Officer | M-Exempt | D | Common Stock Option | 22,376 | 3.62 | 81.0K | 100,000 | — | ↗ |
| 2021-02-01 | Kim Jong Joseph | Director / Officer | S-Sale | D | Common Stock | 100,000 | 15.00 | 1.50M | 1,078,313 | — | ↗ |
| 2021-01-28 | Shea Jacqueline Elizabeth | Officer | M-Exempt | D | Common Stock Option | 55,248 | 3.62 | 200.0K | 122,376 | — | ↗ |
| 2021-01-27 | Shea Jacqueline Elizabeth | Officer | S-Sale | D | Common Stock | 22,376 | 12.01 | 268.7K | 11,920 | — | ↗ |
| 2021-01-15 | Shepard Jay | Director | M-Exempt | A | Common Stock | 4,274 | 0.00 | — | 4,274 | — | ↗ |
| 2021-01-15 | KIES PETER | Officer | M-Exempt | A | Common Stock | 30,000 | 4.56 | 136.8K | 149,290 | — | ↗ |
| 2021-01-05 | Zoth Lota S. | Director | S-Sale | D | Common Stock | 961 | 9.48 | 9.1K | 15,232 | — | ↗ |
| 2021-01-04 | BENITO SIMON X | Director | M-Exempt | A | Common Stock | 2,750 | 3.56 | 9.8K | 54,400 | — | ↗ |
| 2021-01-03 | Zoth Lota S. | Director | M-Exempt | A | Common Stock | 4,090 | 0.00 | — | 16,193 | — | ↗ |
| 2020-12-29 | Kim Jong Joseph | Director / Officer | G-Gift | D | Common Stock | 10,000 | 0.00 | — | 1,178,313 | — | ↗ |
| 2020-12-15 | Weiner David B. | Director | M-Exempt | D | Common Stock Option | 17,500 | 4.56 | 79.8K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-6.3K
Shares Outstanding
53.59M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jacqueline E. Shea, Ph.D. President and Chief Executive Officer | 728.0K | — | 346.1K | 352.0K | 144.1K | 17.0K | 1.59M | 43.98% | ↗ |
| 2 | 2025 | Michael Sumner, M.D. Chief Medical Officer and Head of Development | 548.7K | — | 127.6K | 129.6K | 87.4K | 17.4K | 910.6K | 28.24% | ↗ |
| 3 | 2025 | Peter D. Kies Chief Financial Officer | 514.6K | — | 117.5K | 117.9K | 68.2K | 15.4K | 833.7K | 28.24% | ↗ |
| 4 | 2024 | Jacqueline E. Shea, Ph.D. President and Chief Executive Officer | 728.0K | — | 490.8K | 476.0K | 340.7K | 15.2K | 2.05M | 47.15% | ↗ |
| 5 | 2024 | Michael Sumner, M.D. Chief Medical Officer and Head of Development | 532.0K | 47.1K | 139.6K | 136.3K | 167.1K | 15.3K | 1.04M | 26.60% | ↗ |
| 6 | 2024 | Michael Sumner, M.D. Chief Medical Officer | 532.0K | 47.1K | 139.6K | 136.3K | 167.1K | 15.3K | 1.04M | 26.60% | ↗ |
| 7 | 2024 | Peter D. Kies Chief Financial Officer | 506.8K | — | 132.0K | 128.0K | 158.1K | 15.2K | 940.1K | 27.65% | ↗ |
| 8 | 2023 | Jacqueline E. Shea, Ph.D. President and Chief Executive Officer | 750.6K | — | 491.9K | 813.0K | 371.3K | 12.1K | 2.44M | 53.50% | ↗ |
| 9 | 2023 | Peter D. Kies Chief Financial Officer | 622.9K | — | 132.3K | 218.6K | 172.3K | 15.0K | 1.16M | 30.22% | ↗ |
| 10 | 2023 | Laurent M. Humeau, Ph.D. Chief Scientific Officer | 610.9K | — | 132.3K | 218.6K | 168.3K | 15.0K | 1.14M | 30.64% | ↗ |
| 11 | 2022 | J. Joseph Kim, Ph.D. Former President and Chief Executive Officer | 523.7K | — | 2.98M | 4.26M | — | 2.71M | 10.47M | 69.15% | ↗ |
| 12 | 2022 | Jacqueline E. Shea, Ph.D. President and Chief Executive Officer | 729.8K | — | 1.17M | 1.27M | 336.0K | 13.5K | 3.52M | 69.33% | ↗ |
| 13 | 2022 | Peter D. Kies Chief Financial Officer | 518.6K | — | 463.4K | 466.4K | 155.9K | 14.2K | 1.62M | 57.45% | ↗ |
| 14 | 2022 | Laurent M. Humeau, Ph.D. Chief Scientific Officer | 508.3K | — | 446.9K | 449.9K | 152.3K | 13.0K | 1.57M | 57.11% | ↗ |
| 15 | 2021 | J. Joseph Kim, Ph.D. Former President and Chief Executive Officer | 844.1K | — | 2.29M | 2.63M | 451.4K | 13.0K | 6.22M | 78.98% | ↗ |
| 16 | 2021 | J. Joseph Kim, Ph.D. President and Chief Executive Officer | 844.1K | — | 2.29M | 2.63M | 451.4K | 13.0K | 6.22M | 78.98% | ↗ |
| 17 | 2021 | Jacqueline E. Shea, Ph.D. Chief Operating Officer | 467.6K | — | 750.7K | 860.6K | 218.4K | 12.8K | 2.31M | 69.75% | ↗ |
| 18 | 2021 | Jacqueline E. Shea, Ph.D. President and Chief Executive Officer | 467.6K | — | 750.7K | 860.6K | 218.4K | 12.8K | 2.31M | 69.75% | ↗ |
| 19 | 2021 | Peter D. Kies Chief Financial Officer | 496.2K | — | 750.7K | 860.6K | 179.0K | 11.4K | 2.30M | 70.12% | ↗ |
| 20 | 2021 | Peter D. Kies Chief Financial Officer | 496.2K | — | 750.7K | 860.6K | 179.0K | 11.4K | 2.30M | 70.12% | ↗ |
| 21 | 2021 | Laurent M. Humeau, Ph.D. Chief Scientific Officer | 484.5K | — | 750.7K | 860.6K | 174.8K | 13.0K | 2.28M | 70.56% | ↗ |
| 22 | 2021 | Laurent M. Humeau, Ph.D. Chief Scientific Officer | 484.5K | — | 750.7K | 860.6K | 174.8K | 13.0K | 2.28M | 70.56% | ↗ |
| 23 | 2020 | J. Joseph Kim, Ph.D. President and Chief Executive Officer | 694.6K | — | 3.50M | — | 500.0K | 13.0K | 4.71M | 74.35% | ↗ |
| 24 | 2020 | Peter D. Kies Chief Financial Officer | 445.6K | — | 1.50M | — | 198.3K | 10.0K | 2.15M | 69.64% | ↗ |
| 25 | 2020 | Laurent M. Humeau, Ph.D. Chief Scientific Officer | 430.8K | — | 1.50M | — | 193.6K | 13.0K | 2.14M | 70.18% | ↗ |
| 26 | 2020 | Jacqueline E. Shea, Ph.D. Chief Operating Officer | 430.8K | — | 1.50M | — | 193.6K | 12.9K | 2.14M | 70.18% | ↗ |
| 27 | 2019 | J. Joseph Kim President, Chief Executive Officer and Director | 837.7K | — | 638.3K | 642.8K | 457.2K | 12.5K | 2.59M | 49.49% | ↗ |
| 28 | 2019 | J. Joseph Kim, Ph.D. President and Chief Executive Officer | 837.7K | — | 638.3K | 642.8K | 457.2K | 12.5K | 2.59M | 49.49% | ↗ |
| 29 | 2019 | Mark L. Bagarazzi Former Chief Medical Officer | 214.3K | — | 199.4K | 892.1K | — | 1.02M | 2.32M | 46.95% | ↗ |
| 30 | 2019 | Jacqueline E. Shea, Ph.D. Chief Operating Officer | 335.0K | — | 181.0K | 465.1K | 165.8K | 10.2K | 1.16M | 55.84% | ↗ |
| 31 | 2019 | Jacqueline E. Shea Chief Operating Officer | 335.0K | — | 181.0K | 465.1K | 165.8K | 10.2K | 1.16M | 55.84% | ↗ |
| 32 | 2019 | Peter D. Kies Chief Financial Officer | 523.3K | — | 215.1K | 216.7K | 177.8K | 10.0K | 1.14M | 37.78% | ↗ |
| 33 | 2019 | Laurent M. Humeau Chief Scientific Officer | 393.9K | — | 199.4K | 201.0K | 165.8K | 12.5K | 972.5K | 41.17% | ↗ |
| 34 | 2019 | Laurent M. Humeau, Ph.D. Chief Scientific Officer | 393.9K | — | 199.4K | 201.0K | 165.8K | 12.5K | 972.5K | 41.17% | ↗ |
| 35 | 2018 | J. Joseph Kim, Ph.D. President and Chief Executive Officer | 726.8K | — | 1.55M | 391.9K | 407.4K | 9.3K | 3.08M | 62.89% | ↗ |
| 36 | 2018 | J. Joseph Kim President, Chief Executive Officer and Director | 726.8K | — | 1.55M | 391.9K | 407.4K | 9.3K | 3.08M | 62.89% | ↗ |
| 37 | 2018 | Dr. J. Joseph Kim President, Chief Executive Officer and Director | 726.8K | — | 1.55M | 391.9K | 407.4K | 9.3K | 3.08M | 62.89% | ↗ |
| 38 | 2018 | Dr. Niranjan Y. Sardesai Former Chief Operating Officer | 448.1K | — | 354.8K | 358.6K | 171.2K | 15.3K | 1.35M | 52.92% | ↗ |
| 39 | 2018 | Mark L. Bagarazzi Former Chief Medical Officer | 448.1K | — | 354.8K | 358.6K | 171.2K | 13.2K | 1.35M | 53.01% | ↗ |
| 40 | 2018 | Dr. Mark L. Bagarazzi Former Chief Medical Officer | 448.1K | — | 354.8K | 358.6K | 171.2K | 13.2K | 1.35M | 53.01% | ↗ |
| 41 | 2018 | Peter D. Kies Chief Financial Officer | 449.9K | — | 354.8K | 358.6K | 158.3K | 10.0K | 1.33M | 53.57% | ↗ |
| 42 | 2017 | J. Joseph Kim President, Chief Executive Officer and Director | 780.0K | — | 3.05M | 188.8K | 353.6K | 15.1K | 4.39M | 73.83% | ↗ |
| 43 | 2017 | Dr. J. Joseph Kim President, Chief Executive Officer and Director | 780.0K | — | 3.05M | 188.8K | 353.6K | 15.1K | 4.39M | 73.83% | ↗ |
| 44 | 2017 | Dr. J. Joseph Kim, President, Chief Executive Officer and Director | 780.0K | — | 3.05M | 188.8K | 353.6K | 15.1K | 4.39M | 73.83% | ↗ |
| 45 | 2017 | Dr. Niranjan Y. Sardesai, Chief Operating Officer | 435.1K | — | 450.1K | 437.6K | 148.8K | 9.2K | 1.48M | 59.95% | ↗ |
| 46 | 2017 | Dr. Niranjan Y. Sardesai Former Chief Operating Officer | 435.1K | — | 450.1K | 437.6K | 148.8K | 9.2K | 1.48M | 59.95% | ↗ |
| 47 | 2017 | Peter D. Kies, Chief Financial Officer | 452.8K | — | 409.5K | 437.6K | 137.5K | 10.0K | 1.45M | 58.52% | ↗ |
| 48 | 2017 | Peter D. Kies Chief Financial Officer | 452.8K | — | 409.5K | 437.6K | 137.5K | 10.0K | 1.45M | 58.52% | ↗ |
| 49 | 2017 | Dr. Mark L. Bagarazzi, Chief Medical Officer | 435.1K | — | 409.5K | 437.6K | 148.8K | 13.8K | 1.44M | 58.63% | ↗ |
| 50 | 2017 | Dr. Mark L. Bagarazzi Former Chief Medical Officer | 435.1K | — | 409.5K | 437.6K | 148.8K | 13.8K | 1.44M | 58.63% | ↗ |
| 51 | 2017 | Mark L. Bagarazzi Former Chief Medical Officer | 435.1K | — | 409.5K | 437.6K | 148.8K | 13.8K | 1.44M | 58.63% | ↗ |
| 52 | 2016 | Dr. J. Joseph Kim President, Chief Executive Officer and Director | 643.6K | — | 1.21M | 741.1K | 371.6K | 9.9K | 2.97M | 65.53% | ↗ |
| 53 | 2016 | Dr. J. Joseph Kim, President, Chief Executive Officer and Director | 643.6K | — | 1.21M | 741.1K | 371.6K | 9.9K | 2.97M | 65.53% | ↗ |
| 54 | 2016 | Dr. Mark L. Bagarazzi, Chief Medical Officer | 408.5K | — | 526.5K | 290.8K | 156.3K | 11.7K | 1.39M | 58.64% | ↗ |
| 55 | 2016 | Dr. Mark L. Bagarazzi Former Chief Medical Officer | 408.5K | — | 526.5K | 290.8K | 156.3K | 11.7K | 1.39M | 58.64% | ↗ |
| 56 | 2016 | Dr. Niranjan Y. Sardesai, Chief Operating Officer | 409.7K | — | 526.5K | 290.8K | 156.3K | 9.4K | 1.39M | 58.68% | ↗ |
| 57 | 2016 | Dr. Niranjan Y. Sardesai Former Chief Operating Officer | 409.7K | — | 526.5K | 290.8K | 156.3K | 9.4K | 1.39M | 58.68% | ↗ |
| 58 | 2016 | Peter D. Kies, Chief Financial Officer | 385.6K | — | 526.5K | 290.9K | 144.5K | 8.3K | 1.36M | 60.29% | ↗ |
| 59 | 2016 | Peter D. Kies Chief Financial Officer | 385.6K | — | 526.5K | 290.9K | 144.5K | 8.3K | 1.36M | 60.29% | ↗ |
| 60 | 2015 | Dr. J. Joseph Kim, President, Chief Executive Officer and Director | 698.6K | — | 863.1K | 582.7K | 381.0K | 8.6K | 2.53M | 57.06% | ↗ |
| 61 | 2015 | Dr. Mark L. Bagarazzi, Chief Medical Officer | 391.0K | — | 189.0K | 273.6K | 155.8K | 8.6K | 1.02M | 45.44% | ↗ |
| 62 | 2015 | Dr. Niranjan Y. Sardesai, Chief Operating Officer | 391.0K | — | 189.0K | 273.6K | 155.8K | 8.4K | 1.02M | 45.45% | ↗ |
| 63 | 2015 | Peter D. Kies, Chief Financial Officer | 393.2K | — | 189.0K | 273.6K | 144.0K | 7.0K | 1.01M | 45.95% | ↗ |
| 64 | 2014 | Dr. J. Joseph Kim, President, Chief Executive Officer and Director | 602.1K | 362.6K | — | 1.13M | — | 10.6K | 2.10M | 53.65% | ↗ |
| 65 | 2014 | Dr. Mark L. Bagarazzi, Chief Medical Officer | 353.2K | 137.9K | — | 659.9K | — | 10.8K | 1.16M | 56.80% | ↗ |
| 66 | 2014 | Dr. Niranjan Y. Sardesai, Chief Operating Officer | 348.9K | 137.9K | — | 659.9K | — | 11.3K | 1.16M | 56.98% | ↗ |
| 67 | 2014 | Peter D. Kies, Chief Financial Officer | 347.9K | 127.5K | — | 659.9K | — | 6.4K | 1.14M | 57.80% | ↗ |
| 68 | 2013 | Dr. J. Joseph Kim, President, Chief Executive Officer and Director | 539.8K | 313.0K | — | 170.5K | — | 8.4K | 1.03M | 16.53% | ↗ |
| 69 | 2013 | Peter D. Kies, Chief Financial Officer | 318.8K | 103.1K | — | 71.4K | — | 5.8K | 499.1K | 14.30% | ↗ |
| 70 | 2013 | Dr. Mark L. Bagarazzi, Chief Medical Officer | 307.6K | 106.7K | — | 71.4K | — | 8.3K | 494.0K | 14.45% | ↗ |
| 71 | 2013 | Dr. Niranjan Y. Sardesai, Chief Operating Officer | 303.1K | 106.7K | — | 71.4K | — | 8.3K | 489.4K | 14.59% | ↗ |
| 72 | 2012 | Dr. J. Joseph Kim, President, Chief Executive Officer and Director | 545.8K | 211.2K | — | 201.0K | — | 7.8K | 965.8K | 20.81% | ↗ |
| 73 | 2012 | Dr. Niranjan Y. Sardesai, Chief Operating Officer | 294.0K | 72.0K | — | 102.4K | — | 7.0K | 475.3K | 21.54% | ↗ |
| 74 | 2012 | Dr. Niranjan Y. Sardesei, Chief Operating Officer | 294.0K | 72.0K | — | 102.4K | — | 7.0K | 475.3K | 21.54% | ↗ |
| 75 | 2012 | Peter D. Kies, Chief Financial Officer | 301.5K | 69.6K | — | 84.7K | — | 5.4K | 461.2K | 18.37% | ↗ |
| 76 | 2012 | Dr. Mark L. Bagarazzi, Chief Medical Officer | 296.2K | 72.0K | — | 84.7K | — | 6.9K | 459.8K | 18.43% | ↗ |
| 77 | 2011 | Dr. J. Joseph Kim, President, Chief Executive Officer and Director | 422.3K | 237.6K | — | 235.4K | — | 8.3K | 903.6K | 26.05% | ↗ |
| 78 | 2011 | Dr. Avtar Dhillon, Non-Executive Chairman; Former Executive Chairman | 296.3K | 59.5K | — | 141.3K | — | 160.1K | 657.2K | 21.49% | ↗ |
| 79 | 2011 | Dr. Niranjan Y. Sardesei, Chief Operating Officer | 258.8K | 81.0K | — | 113.0K | — | 6.9K | 459.8K | 24.58% | ↗ |
| 80 | 2011 | Dr. Niranjan Y. Sardesai, Chief Operating Officer | 258.8K | 81.0K | — | — | — | 6.9K | 459.8K | 0.00% | ↗ |
| 81 | 2011 | Peter D. Kies, Chief Financial Officer | 257.4K | 78.3K | — | — | — | 4.8K | 453.4K | 0.00% | ↗ |
| 82 | 2011 | Dr. Mark L. Bagarazzi, Chief Medical Officer | 246.6K | 81.0K | — | — | — | 4.4K | 445.0K | 0.00% | ↗ |
| 83 | 2010 | Dr. Avtar Dhillon, Non-Executive Chairman; Former Executive Chairman | 374.9K | 480.0K | — | — | — | 5.2K | 860.2K | 0.00% | ↗ |
| 84 | 2010 | Dr. Avtar Dhillon, Executive Chairman; Former Chief Executive Officer | 374.9K | 480.0K | — | — | — | 5.2K | 860.2K | 0.00% | ↗ |
| 85 | 2010 | Dr. J. Joseph Kim, President, Chief Executive Officer and Director | 362.5K | 153.1K | — | — | — | 9.1K | 524.7K | 0.00% | ↗ |
| 86 | 2010 | Dr. J. Joseph Kim President, Chief Executive Officer and Director | 362.5K | 153.1K | — | — | — | 9.1K | 524.7K | 0.00% | ↗ |
| 87 | 2010 | Peter D. Kies, Chief Financial Officer | 229.6K | 51.8K | — | — | — | 1.4K | 282.7K | 0.00% | ↗ |
| 88 | 2010 | Dr. Niranjan Y. Sardesei, Chief Operating Officer | — | — | — | — | — | — | — | — | ↗ |
| 89 | 2010 | Dr. Mark L. Bagarazzi, Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 90 | 2009 | Dr. Avtar Dhillon, Executive Chairman | 370.9K | 444.1K | 120.5K | — | — | 144.8K | 1.33M | 9.09% | ↗ |
| 91 | 2009 | Dr. Avtar Dhillon, Executive Chairman; Former Chief Executive Officer | 370.9K | 444.1K | — | 161.0K | — | 144.8K | 1.12M | 14.36% | ↗ |
| 92 | 2009 | Dr. Avtar Dhillon, Non-Executive Chairman; Former Executive Chairman | 511.9K | 444.1K | — | 161.0K | — | 3.8K | 1.12M | 14.36% | ↗ |
| 93 | 2009 | Dr. J. Joseph Kim, President, Chief Executive Officer and Director | 179.4K | 132.3K | — | 360.5K | — | — | 672.2K | 53.63% | ↗ |
| 94 | 2009 | Dr. J. Joseph Kim President, Chief Executive Officer and Director | 179.4K | 132.3K | — | 360.5K | — | — | 672.2K | 53.63% | ↗ |
| 95 | 2009 | Peter D. Kies, Chief Financial Officer | 223.7K | 255.1K | — | — | — | — | 588.2K | 0.00% | ↗ |
| 96 | 2009 | J. Joseph Kim President, Chief Executive | 179.4K | 132.3K | — | — | — | — | 484.3K | 0.00% | ↗ |
| 97 | 2009 | Niranjan Y. Sardesai, Senior Vice President, | 115.8K | 58.8K | — | — | — | — | 234.8K | 0.00% | ↗ |
| 98 | 2009 | Kevin W. Rassas, Senior Vice President, | 107.2K | 56.3K | — | — | — | — | 212.0K | 0.00% | ↗ |
| 99 | 2009 | Dr. Mark L. Bagarazzi, Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 100 | 2009 | Dr. Niranjan Y. Sardesei, Chief Operating Officer | — | — | — | — | — | — | — | — | ↗ |
| 101 | 2008 | Dr. Avtar Dhillon, Executive Chairman | 369.4K | — | 102.2K | — | — | 18.7K | 668.7K | 15.29% | ↗ |
| 102 | 2008 | Dr. Avtar Dhillon, Executive Chairman; Former Chief Executive Officer | 369.4K | — | 65.3K | 67.4K | — | 18.7K | 520.8K | 25.47% | ↗ |
| 103 | 2008 | Peter Kies, Chief Financial Officer and HR Manager | 220.8K | — | — | 98.9K | — | — | 319.7K | 30.94% | ↗ |
| 104 | 2008 | Peter D. Kies, Chief Financial Officer | 220.8K | — | — | — | — | — | 319.7K | 0.00% | ↗ |
| 105 | 2008 | Iacob Mathiesen, Managing Director, Inovio AS | 188.6K | — | 63.4K | 51.5K | — | — | 303.5K | 37.88% | ↗ |
| 106 | 2008 | Punit Dhillon, Vice President, Operations and Finance | 171.9K | — | — | 85.5K | — | 3.9K | 261.3K | 32.73% | ↗ |
| 107 | 2008 | Michael Fons, Vice President, Corporate Development | 197.1K | — | — | 59.8K | — | 3.2K | 260.1K | 23.00% | ↗ |
| 108 | 2008 | Kevin W. Rassas, Senior Vice President, | — | — | — | — | — | — | — | — | ↗ |
| 109 | 2008 | Niranjan Y. Sardesai, Senior Vice President, | — | — | — | — | — | — | — | — | ↗ |
| 110 | 2008 | J. Joseph Kim President, Chief Executive | — | — | — | — | — | — | — | — | ↗ |
| 111 | 2008 | Dr. J. Joseph Kim President, Chief Executive Officer and Director | — | — | — | — | — | — | — | — | ↗ |
| 112 | 2007 | Dr. Avtar Dhillon, President and Chief Executive Officer | 357.5K | 116.4K | 69.2K | 391.4K | — | 5.3K | 939.8K | 49.01% | ↗ |
| 113 | 2007 | Iacob Mathiesen, Managing Director, Inovio AS | 179.4K | — | 166.1K | 63.0K | — | — | 408.5K | 56.07% | ↗ |
| 114 | 2007 | Peter Kies, Chief Financial Officer and HR Manager | 207.0K | 26.6K | — | 128.2K | — | — | 361.8K | 35.45% | ↗ |
| 115 | 2007 | Michael Fons, Vice President, Corporate Development | 188.2K | 16.6K | — | 81.9K | — | 3.3K | 290.0K | 28.23% | ↗ |
| 116 | 2007 | Punit Dhillon, Vice President, Operations and Finance | 145.7K | 13.3K | — | 94.0K | — | 3.9K | 257.0K | 36.59% | ↗ |
| 117 | 2007 | Dietmar Rabussay, Vice President, Research and Development | 185.4K | — | — | 63.9K | — | 5.2K | 254.5K | 25.12% | ↗ |
| 118 | 2006 | Avtar Dhillon, President and Chief Executive Officer | 328.0K | 150.5K | — | 415.7K | — | 4.3K | 898.4K | 46.27% | ↗ |
| 119 | 2006 | George McHugh, Vice President, Operations | 173.6K | 29.0K | — | 48.0K | — | 85.5K | 336.1K | 14.28% | ↗ |
| 120 | 2006 | Peter Kies, Chief Financial Officer and HR Manager | 186.2K | 40.0K | — | 73.1K | — | — | 299.3K | 24.42% | ↗ |
| 121 | 2006 | Robert Goodenow, Vice President, Corporate Development | 186.1K | — | — | 74.1K | — | — | 260.2K | 28.49% | ↗ |
| 122 | 2006 | Dietmar Rabussay, Vice President, Research and Development | 175.0K | 10.0K | — | 66.1K | — | 5.2K | 256.3K | 25.79% | ↗ |
| 123 | 2005 | Avtar Dhillon, M.D. President and CEO | 312.0K | 135.0K | — | 150.0K | — | 7.0K | 454.0K | 33.04% | ↗ |
| 124 | 2005 | Peter D. Kies Chief Financial Officer | 180.0K | 30.0K | — | 20.0K | — | — | 210.0K | 9.52% | ↗ |
| 125 | 2005 | Robert Goodenow, Ph.D Vice President, Corporate Development | 180.0K | 20.0K | — | 20.0K | — | — | 200.0K | 10.00% | ↗ |
| 126 | 2005 | Dietmar Rabussay, Ph.D Vice President, Research Development | 173.6K | 15.0K | — | 10.0K | — | 5.2K | 193.8K | 5.16% | ↗ |
| 127 | 2005 | Walter Singleton, M.D. Vice President, Clinical | 186.9K | — | — | — | — | 5.2K | 192.0K | 0.00% | ↗ |
| 128 | 2005 | George McHugh Vice President, Operations | 165.0K | 20.0K | — | 15.0K | — | — | 185.0K | 8.11% | ↗ |
| 129 | 2004 | Avtar Dhillon, M.D. President and CEO | 324.6K | 139.5K | — | 125.0K | — | 6.5K | 470.6K | 26.56% | ↗ |
| 130 | 2004 | Robert Goodenow, Ph.D Vice President, Corporate Development | 177.6K | 10.0K | — | — | — | — | 187.6K | 0.00% | ↗ |
| 131 | 2004 | Peter D. Kies Chief Financial Officer | 186.7K | — | — | — | — | — | 186.7K | 0.00% | ↗ |
| 132 | 2004 | Dietmar Rabussay, Ph.D Vice President, Research Development | 180.3K | — | — | 32.4K | — | 4.0K | 184.3K | 17.60% | ↗ |
| 133 | 2004 | George McHugh Vice President, Operations | 115.5K | — | — | 37.5K | — | — | 115.5K | 32.47% | ↗ |
| 134 | 2004 | George McHugh Vice President, Operations | 115.5K | — | — | — | — | — | 115.5K | 0.00% | ↗ |
| 135 | 2004 | Walter Singleton, M.D. Vice President, Clinical | 70.4K | — | — | 125.0K | — | — | 70.4K | 177.59% | ↗ |
| 136 | 2004 | Walter Singleton, M.D. Vice President, Clinical Regulatory Affairs | 70.4K | — | — | — | — | — | 70.4K | 0.00% | ↗ |
| 137 | 2003 | Avtar Dhillon, M.D. President and CEO | 238.0K | 78.0K | — | 725.0K | — | 5.1K | 321.1K | 225.81% | ↗ |
| 138 | 2003 | Dietmar Rabussay, Ph.D Vice President, Research Development | 159.6K | — | — | — | — | 2.6K | 162.2K | 0.00% | ↗ |
| 139 | 2003 | Dietmar Rabussay, Ph.D Vice President, Research Development | 159.6K | — | — | 129.8K | — | 2.6K | 162.2K | 80.01% | ↗ |
| 140 | 2003 | Peter D. Kies Chief Financial Officer | 159.5K | — | — | 107.5K | — | — | 159.5K | 67.40% | ↗ |
| 141 | 2003 | Robert Goodenow, Ph.D Vice President, Corporate Development | 150.6K | — | — | 30.0K | — | — | 150.6K | 19.91% | ↗ |
| 142 | 2003 | Robert Goodenow, Ph.D Vice President, Corporate Development | 150.6K | — | — | 120.0K | — | — | 150.6K | 79.66% | ↗ |
| 143 | 2003 | Brook Riggins Vice President, Finance and Corporate Communications | 118.0K | — | — | 277.5K | — | — | 118.0K | 235.24% | ↗ |
| 144 | 2002 | Avtar Dhillon, M.D. President and CEO | 203.4K | 55.0K | — | 650.0K | — | 4.2K | 262.6K | 247.57% | ↗ |
| 145 | 2002 | Dietmar Rabussay, Ph.D Vice President, Research Development | 157.5K | — | — | 60.0K | — | 2.6K | 160.1K | 37.48% | ↗ |
| 146 | 2002 | Brook Riggins Vice President, Finance and Corporate Communications | 89.7K | — | — | 260.0K | — | — | 89.7K | 289.76% | ↗ |
| 147 | 2002 | Peter D. Kies Chief Financial Officer | 57.2K | — | — | 180.0K | — | — | 57.2K | 314.62% | ↗ |
| 148 | 2002 | Robert Goodenow, Ph.D Vice President, Corporate Development | 17.3K | — | — | 230.0K | — | — | 17.3K | 1,330.40% | ↗ |
| 149 | 2001 | Martin Nash Former Director, President and Chief Executive Officer | 230.8K | — | — | — | — | — | 230.8K | 0.00% | ↗ |
| 150 | 2001 | George M. Gill Former Vice President, Clinical Research and Regulatory Affairs | 150.0K | — | — | — | — | — | 150.0K | 0.00% | ↗ |
| 151 | 2001 | Terry Gibson Chief Operating Officer | 113.1K | 21.0K | — | — | — | — | 134.1K | 0.00% | ↗ |
| 152 | 2001 | James C. Lierman Former Executive Vice President | 99.1K | 4.2K | — | — | — | — | 103.3K | 0.00% | ↗ |
| 153 | 2001 | Avtar Dhillon, M.D. President and CEO | 36.9K | — | — | 400.0K | — | — | 36.9K | 1,083.36% | ↗ |
| 154 | 2000 | Martin Nash Former Director, President and Chief Executive Officer | 201.8K | — | — | — | — | — | 201.8K | 0.00% | ↗ |
| 155 | 2000 | James C. Lierman Former Executive Vice President | 155.8K | 20.8K | — | — | — | — | 176.6K | 0.00% | ↗ |
| 156 | 2000 | George M. Gill Former Vice President, Clinical Research and Regulatory Affairs | 47.9K | — | — | — | — | — | 47.9K | 0.00% | ↗ |
| 157 | 2000 | Terry Gibson Chief Operating Officer | — | — | — | — | — | — | — | — | ↗ |
| 158 | 1999 | Martin Nash Former Director, President and Chief Executive Officer | 140.6K | 27.2K | — | — | — | — | 167.8K | 0.00% | ↗ |
| 159 | 1999 | George M. Gill Former Vice President, Clinical Research and Regulatory Affairs | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jacqueline E. Shea | Chief Executive Officer, President & Director | 889.1K | — |
| Laurent Humeau | Chief Scientific Officer & Chairman of the Scientific Advisory Board | 794.1K | — |
| Michael Sumner | Chief Medical Officer & Head of Development | 653.5K | — |
| Peter D. Kies | Chief Financial Officer | 598.3K | male |
| Robert L. Crotty | General Counsel, Corporate Secretary & Chief Compliance Officer | — | male |
| Shawn D. Bridy | Senior Vice President of Business Development | — | male |
| E. J. Brandreth | Senior Vice President of Quality Assurance | — | male |
| Thomas Hong | Manager of Investor Relations | — | — |
| Jeffrey Skolnik | Senior Vice President of Clinical Development | — | — |
| Jennie Willson | Director of Communications | — | female |
| Robert J. Juba Jr. | Senior Vice President of Biological Manufacturing & Clinical Supply Management | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2020-09-08 | 2020-11-06 | Chris Jacobs | NY27 | — | Sale (Full) | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for INO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
